肠促胰素类药物治疗糖尿病的潜在风险  

Potential Risks of Incretin-Based Therapy in Type 2 Diabetes Mellitus

作　　者：陈一文[1] 梁颖慧[1] 王宁[1] 

机构地区：[1]首都医科大学附属北京同仁医院干部医疗科,北京100730

出　　处：《临床药物治疗杂志》2014年第2期25-29,共5页Clinical Medication Journal

摘　　要：目的:总结分析肠促胰素类药物治疗糖尿病的潜在风险。方法:收集近来国内外相关报道并进行分析。结果和结论:肠促胰岛素类药物的血糖控制及减轻体重疗效不劣于其他降糖药物,且低血糖发生率低,故其问世以来得到广泛应用。但相关流行病学调查、动物实验及临床研究均提示应用该类药物存在胰腺病变及促进肿瘤发生的潜在风险,其药物安全性备受关注,为正确评价药物安全性需进一步完善高质量的临床研究。Objective： To analyzed potential risks of incretin-based therapy in type 2 diabetes mel itus. Methods： we col ected and analyzed related publications.Results and Conclusions： Drugs based-on incretins are widely used since being launched, for their efifcacy in glucose control and weigh loss are as good as other hypoglycemic agents, and their prevalence of hypoglycemia are low. However, epidemiology, animal research and clinical studies show that incretin-based therapies potential y increase risks of pancreatic lesions and tumor. So we should pay more attention to the safety of the incretins. Appropriate evaluation relies on high quality clinical trails.

关 键 词：肠促胰岛素类药物 药物不良反应 2型糖尿病 

分 类 号：R563[医药卫生—呼吸系统] R97[医药卫生—内科学]